Are you at risk for a heart attack or stroke? >>
Recent research suggests that a simple blood test may show inflammation of the arteries, which may be an early indicator of cardiovascular disease — even in people with normal or low cholesterol. Dr. Paul Ridker of Brigham & Women’s Hospital and Astra Zeneca Pharmaceuticals are leading an investigation of a new test of inflammation called C-reactive protein. This may be a more powerful predictor of heart attack than cholesterol. The purpose of this trial - known as the Jupiter Study - is to investigate whether rosuvastatin, a new statin drug, is helpful in preventing major cardiovascular events such as heart attack, stroke, and cardiac death in patients with normal cholesterol and elevated C-reactive protein.
Qualifications for this study include:
- men 55 years and older
- women 65 years and older
- no prior history of heart attacks, stroke, or diabetes
- not already taking a cholesterol lowering drug.
To see if you — or someone you care about — would qualify, or to find out more about the study, contact: Steven Schwartz, MD, FACC, Lahey Cardiology at The Medical Center, 603-577-2039.
Southern New Hampshire Medical Center participates in clinical trials that focus on innovative treatments and seek to improve care for patients with diseases like heart disease. Patients who participate receive free, state-of-the-art treatment, close to home.
|
